COMMUNIQUÉS West-GlobeNewswire

Certara to Participate in the Stephens Annual Investment Conference
28/10/2024
RADNOR, Pa., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that Company management will participate in the Stephens Annual Investment [...]
UPDATE -- BioVie Inc. Announces Pricing of Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
28/10/2024
CARSON CITY, Nev., Oct. 28, 2024 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions [...]
Inari Medical Reports Third Quarter 2024 Financial Results
28/10/2024
IRVINE, Calif., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other [...]
Shuttle Pharma Completes Clinical Trial Site Enrollment for Phase 2 of Ropidoxuridine for Treatment of Patients with Glioblastoma
28/10/2024
GAITHERSBURG, Md., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma”), a discovery and development stage specialty pharmaceutical company focused on improving [...]
Ardelyx Presents Results from its IBS in America 2024 Supplemental Survey at the American College of Gastroenterology’s (ACG) Annual Meeting
28/10/2024
Ninety percent of survey participants reported “some” or “significant” negative impact of IBS-C on their life Survey results presented in two poster presentations WALTHAM, Mass., Oct. 28, 2024 (GLOBE NEWSWIRE) -- [...]
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
28/10/2024
WATERTOWN, Mass., Oct. 28, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced [...]
Monopar Therapeutics Inc. Announces Proposed Public Offering of Common Stock
28/10/2024
WILMETTE, Ill., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) (“Monopar Therapeutics” or the “Company”) , a clinical-stage biotechnology company focused on developing innovative treatments [...]
BioVie Inc. Announces Pricing of Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
28/10/2024
CARSON CITY, Nev., Oct. 28, 2024 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions [...]
Sonablate announces first patient enrolled in HIFIVE U.S. clinical trial for ablation of incompetent veins
28/10/2024
HIFIVE is a single arm, single institution, Phase I trial to assess the safety and performance of Sonablate high-intensity focused ultrasound for treating incompetent veins including vascular malformations CHARLOTTE, N. [...]
Elixir Medical’s DynamX Bioadaptor Demonstrates Significant Improvement Over Contemporary Drug-Eluting Stent in Patients with Acute Coronary Syndrome and Complex Lesion Subsets After Six Months
28/10/2024
Elixir Medical’s DynamX Bioadaptor Demonstrates Significant Improvement Over Contemporary Drug-Eluting Stent in Patients with Acute Coronary Syndrome and Complex Lesion Subsets After Six Months —Late-breaking 12-month [...]
Après six mois, le DynamX Bioadaptor d’Elixir Medical fait preuve d’une amélioration importante en comparaison des stents à élution médicamenteuse (DES), chez les patients atteints de syndrome coronarien aigu et de lésions complexes
28/10/2024
Après six mois, le DynamX Bioadaptor d’Elixir Medical fait preuve d’une amélioration importante en comparaison des stents à élution médicamenteuse (DES), chez les patients atteints de syndrome coronarien aigu et de [...]
BioStem Technologies to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024
28/10/2024
Conference Call and Webcast to be held at 4:30 PM ET POMPANO BEACH, Fla., Oct. 28, 2024 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacture, and [...]
Oxford Treatment Center Leads the Way in Delivering Veteran Ready Care with New PsychArmor Certification
28/10/2024
ETTA, Miss., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Oxford Treatment Center has joined a small group of addiction treatment providers across the nation that have achieved Veteran Ready Certification from PsychArmor, a [...]
AB Science receives notice of allowance for European patent covering masitinib until 2040 in the treatment of sickle cell disease
28/10/2024
PRESS RELEASE AB SCIENCE RECEIVES NOTICE OF ALLOWANCE FOR EUROPEAN PATENT COVERING MASITINIB UNTIL 2040 IN THE TREATMENT OF SICKLE CELL DISEASE THIS DECISION FURTHER STRENGTHENS MASITINIB’S INTELLECTUAL PROPERTY ADDING [...]
AB Science reçoit un avis d’acceptation pour le brevet européen couvrant jusqu’en 2040 le masitinib dans le traitement de la drépanocytose
28/10/2024
COMMUNIQUE DE PRESSE AB SCIENCE REÇOIT UN AVIS D'ACCEPTATION POUR LE BREVET EUROPÉEN COUVRANT JUSQU'EN 2040 LE MASITINIB DANS LE TRAITEMENT DE LA DREPANOCYTOSE CETTE DÉCISION RENFORCE LA PROPRIÉTÉ INTELLECTUELLE DU [...]
ONWARD® Medical Publishes Closing of Bookbuild Offering
28/10/2024
THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE (7)(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014) EINDHOVEN, the Netherlands, Oct. 28, 2024 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. ( [...]
IHA selects Cozeva as their sole analytics partner for all performance measurement programs
28/10/2024
Expanded partnership between IHA and Cozeva will implement redesign of flagship AMP program and drive healthcare quality and equity performance forward in California OAKLAND, Calif., Oct. 28, 2024 (GLOBE NEWSWIRE) -- [...]
BioPorto Enters Global Distribution Partnership with Beckman Coulter for Acute Kidney Injury NGAL Tests
28/10/2024
28 October 2024 Announcement no. 19 BioPorto Enters Global Distribution Partnership with Beckman Coulter for Acute Kidney Injury NGAL Tests COPENHAGEN, DENMARK and BOSTON, MA, USA, October 28, 2024 (GLOBE NEWSWIRE) – [...]
HOPO Therapeutics Awarded Up to $226 Million from BARDA for Advanced Development of its Oral Decorporation Agent for Heavy Metal Toxicity
28/10/2024
BERKELEY, Calif., Oct. 28, 2024 (GLOBE NEWSWIRE) -- HOPO Therapeutics, Inc. announced today that it has been awarded a contract valued at up to $226 million from the Biomedical Advanced Research and Development [...]

Pages